التفاصيل البيبلوغرافية
| العنوان: |
Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. |
| المؤلفون: |
Sumpter, Kathryn M., Adhikari, Soumya, Grishman, Ellen K., White, Perrin C. |
| المصدر: |
Pediatric Diabetes; Nov2011, Vol. 12 Issue 7, p656-667, 12p, 1 Diagram, 4 Charts |
| مصطلحات موضوعية: |
TREATMENT of diabetes, ANALYSIS of variance, AUTOANTIBODIES, BIOLOGICAL assay, BIOPHYSICS, CHILDREN'S hospitals, DIABETES, GENE expression, GLYCOSYLATED hemoglobin, INSULIN, TYPE 1 diabetes, INTERLEUKINS, RESEARCH methodology, METABOLIC regulation, PEDIATRICS, PEPTIDES, RACE, DATA analysis, MICROARRAY technology, DESCRIPTIVE statistics, THERAPEUTICS |
| مستخلص: |
Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Background: Interleukin-1β (IL-1β) may play a role in the pathogenesis of type 1 diabetes, but there are no data regarding the efficacy of agents antagonizing IL-1β in patients with this disorder. We characterized the effects of IL-1β on gene expression in peripheral blood mononuclear cells (PBMC) and the clinical and gene expression effects of a short course of recombinant IL-1 receptor antagonist protein, anakinra, on children with newly diagnosed diabetes. Methods: PBMC from healthy adult volunteers were exposed to IL-1β for 24 h in vitro. Gene expression was analyzed via microarray. Fifteen children within 1 wk of diagnosis of type 1 diabetes received daily anakinra for 28 d and were followed for 6 months. Blood was drawn for microarray analysis before and after anakinra treatment. Insulin secretory capacity was assessed by mixed-meal tolerance testing (MMTT) at 3-4 wk and 7 months after diagnosis. Hemoglobin A1c (HbA1c) and insulin doses were periodically recorded. Data were compared with two historical control groups of children with newly diagnosed diabetes. Results: Although in vitro exposure to IL-1β caused many changes in PBMC gene expression, gene expression did not change significantly after anakinra therapy in diabetes patients. Anakinra-treated patients had similar HbA1c and MMTT responses, but lower insulin requirements 1 and 4 months after diagnosis compared to controls, and lower insulin-dose-adjusted A1c 1 month after diagnosis. Conclusions: Anakinra therapy is well tolerated in children with newly diagnosed type 1 diabetes. Further studies are needed to demonstrate biological effects. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pediatric Diabetes is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder